直 Japanese PDF Font
  • Our Professionals
  • Our Work
  • Our Insights
  • Offices
  • Firm
  • Careers
Finnegan
  • Articles & Books
    • Ad Law Buzz Blog
    • At the PTAB Blog
    • European IP Blog
    • Federal Circuit IP Blog
    • INCONTESTABLE® Blog
    • Prosecution First Blog
  • Events & Webinars
  • IP Updates
  • Podcasts
    • AI + Finnegan
    • AI + Copyright
    • AI + Patent
    • AI + Privacy
    • AI + Trade Secrets
    • AI + Trademark
  • Unified Patent Court (UPC) Hub

At the PTAB Blog

Consistency Is Key – USPTO Issues Three New Informative Decisions

May 29, 2026

Authored and Edited by Forrest A. Jones; William C. Neer; David A. Izzo

On May 13, 2026, the United States Patent and Trademark Office designated as informative three Patent Trial and Appeal Board decisions where the Director denied institution because petitioners advanced indefiniteness or different claim construction arguments in district court without sufficient justification.1In contrast to precedential decisions, informative decisions are not binding, but they do provide the Board guidance on new or reoccurring issues. See Patent Trial and Appeal Board Standard Operating Procedure 2 (Rev. 11) at 3. Terumo BCT, Inc. v. Haemonetics Corp., IPR2025-01374, IPR2025-01391, Paper 20 (Director May 12, 2026), summarized below, is representative of the three new informative decisions.

Terumo BCT, Inc. v. Haemonetics Corp., IPR2025-01374, IPR2025-01391, Paper 20 (Director May 12, 2026) (informative)

In Terumo v. Haemonetics, Director Squires granted Director Review, vacated the Board’s earlier decision granting institution, and denied the petitions, finding petitioner advanced inconsistent claim construction arguments in district court after institution without sufficient justification.

In its petition, petitioner argued that no construction was necessary for the challenged claims and advanced a plain and ordinary meaning for all claim terms. After the Board granted institution, petitioner asserted in district court that certain claims reciting a “controller” are indefinite under 35 U.S.C. § 112(b). Patent owner subsequently filed a request for Director Review, arguing petitioner’s positions are inconsistent between forums and insufficiently explained as required by the other precedential and informative decisions.2

Petitioner provided two justifications in response: (1) the claim term “controller” is not in controversy in the inter partes reviews, and its construction is immaterial to the prior art analysis before the Board; and (2) 37 C.F.R. § 42.104(b)(3), requiring “[w]here the claim to be construed contains a means-plus-function or step-plus-function limitation as permitted under 35 U.S.C. 112(f), the construction of the claim must identify the specific portions of the specification that describe the structure, material, or acts corresponding to each claimed function,” is not implicated because that rule only applies to terms that are in controversy.

The Director found both justifications insufficient to support petitioner’s different claim construction positions of the term “controller” in the district court and at the Board. The Director explained that simply failing to keep consistent constructions across forums detract from the Office’s goal of providing greater predictability and certainty in the patent system. He also rejected petitioner’s mean-plus-function argument because asserting such a construction in district court “undercuts its position that Rule 42.104(b)(3) does not apply here.” The Director concluded that denial was appropriate here because petitioner’s conduct does not provide a litigation alternative, as Congress intended.

Going forward, petitioners should generally avoid presenting different §112 or claim construction positions between district court and AIA proceedings. If petitioners do advance different positions, they should be prepared to justify their decisions to do so. Patent owners should consider whether petitioners take different positions and, when appropriate, inform the Board about these positions.

Endnotes

1Ford Motor Company v. AutoConnect Holdings LLC, IPR2025-01342, -01383, -01524, Paper 27 (Director May 12, 2026); Terumo BCT, Inc. v. Haemonetics Corp., IPR2025-01374, Paper 20 (Director May 12, 2026); TikTok, Inc. v. Shopsee, Inc., IPR2025-01485, Paper 13 (Director Jan. 16, 2026).

2 Revvo Technologies, Inc. v. Cerebrum Sensor Technologies, Inc., IPR2025-00632, Paper 20 (Director Nov. 3, 2025) (precedential); Tesla, Inc. v. Intellectual Ventures II LLC, IPR2025-00340, Paper 18 (Director Nov. 5, 2025) (informative).

Tags

Patent Trial and Appeal Board (PTAB), United States Patent and Trademark Office (USPTO), claim construction, indefiniteness (35 USC § 112)

Related Practices

Global IP Enforcement, Litigation, and Trials

Patent Litigation and Trials

Patent Office Invalidation Proceedings

PTAB Invalidation Proceedings: IPR and PGR

Related Industries

Life Sciences

Medical Device and Diagnostics

Related Offices

Washington, DC

Contacts

Forrest A. Jones
Partner
Washington, DC
+1 202 408 4019
Email
William C. Neer
Associate
Washington, DC
+1 202 408 4054
Email
David A. Izzo
Associate
Washington, DC
+1 202 408 4482
Email

Copyright © 2026 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP. 

DISCLAIMER: Although we wish to hear from you, information exchanged in this blog cannot and does not create an attorney-client relationship. Please do not post any information that you consider to be personal or confidential. If you wish for Finnegan, Henderson, Farabow, Garrett & Dunner, LLP to consider representing you, in order to establish an attorney-client relationship you must first enter a written representation agreement with Finnegan. Contact us for additional information. One of our lawyers will be happy to discuss the possibility of representation with you. Additional disclaimer information.

Related Insights

Conference

17th Summit on Biosimilars & Innovator Biologics

June 2-3, 2026

New York

At the PTAB Blog

Discretion All the Way Down: USPTO Uses a Discretionary IPR Denial to Justify a    
§ 325(d) EPR Denial

May 28, 2026

Articles

Colorado Replaces Landmark AI Act: An Overview of the New SB 26-189 Framework

May 26, 2026

At the PTAB Blog

IPR and PGR Statistics for Final Written Decisions Issued in March and April 2026

May 26, 2026

At the PTAB Blog

Claim Disclaimer Derails Instituted IPR in Freightcar America

May 26, 2026

At the PTAB Blog

Before the Holding, the Message: Director Squires Uses Magnolia Medical to Outline PTAB Discretionary Denial Policy Changes

May 20, 2026

Webinar

Changes at the PTAB from Settled Expectations to Real Parties in Interest to Director Involvement

May 18, 2026

Webinar

Seminar

IP Strategy at the Crossroads: Technology, Enforcement, and Contracts

May 15, 2026

Taipei

Articles

COPPA’s Amended Rule Is Now in Full Effect: What Operators Need to Know

May 15, 2026

Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.

  • Privacy
  • Disclaimer
  • Legal Notices
  • Fraud Alert
  • EEO Statement
  • Cookies
  • Contact Us

© 2026 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP